Myelodysplastic Syndrome - Pipeline Review, H2 2019
Myelodysplastic Syndrome - Pipeline Review, H2 2019
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myelodysplastic Syndrome - Pipeline Review, H2 2019, provides an overview of the Myelodysplastic Syndrome (Oncology) pipeline landscape.
Myelodysplastic syndrome (MDS) is a condition that affects the bone marrow and the blood cells it produces. Myelodysplastic syndromes rarely cause signs or symptoms in the early stages of the disease. Symptoms include fatigue, shortness of breath, unusual paleness (pallor) due to anemia, easy or unusual bruising or bleeding and frequent infections.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myelodysplastic Syndrome - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Myelodysplastic Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 1, 14, 84, 63, 2, 8, 31 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 9, 4 and 3 molecules, respectively.
Myelodysplastic Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myelodysplastic Syndrome - Pipeline Review, H2 2019, provides an overview of the Myelodysplastic Syndrome (Oncology) pipeline landscape.
Myelodysplastic syndrome (MDS) is a condition that affects the bone marrow and the blood cells it produces. Myelodysplastic syndromes rarely cause signs or symptoms in the early stages of the disease. Symptoms include fatigue, shortness of breath, unusual paleness (pallor) due to anemia, easy or unusual bruising or bleeding and frequent infections.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myelodysplastic Syndrome - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Myelodysplastic Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 1, 14, 84, 63, 2, 8, 31 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 9, 4 and 3 molecules, respectively.
Myelodysplastic Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Myelodysplastic Syndrome (Oncology).
- The pipeline guide reviews pipeline therapeutics for Myelodysplastic Syndrome (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Myelodysplastic Syndrome (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Myelodysplastic Syndrome (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Myelodysplastic Syndrome (Oncology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Myelodysplastic Syndrome (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Myelodysplastic Syndrome (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Myelodysplastic Syndrome - Overview
Myelodysplastic Syndrome - Therapeutics Development
Myelodysplastic Syndrome - Therapeutics Assessment
Myelodysplastic Syndrome - Companies Involved in Therapeutics Development
Myelodysplastic Syndrome - Drug Profiles
Myelodysplastic Syndrome - Dormant Projects
Myelodysplastic Syndrome - Discontinued Products
Myelodysplastic Syndrome - Product Development Milestones
Appendix
Myelodysplastic Syndrome - Overview
Myelodysplastic Syndrome - Therapeutics Development
Myelodysplastic Syndrome - Therapeutics Assessment
Myelodysplastic Syndrome - Companies Involved in Therapeutics Development
Myelodysplastic Syndrome - Drug Profiles
Myelodysplastic Syndrome - Dormant Projects
Myelodysplastic Syndrome - Discontinued Products
Myelodysplastic Syndrome - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development for Myelodysplastic Syndrome, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Products under Development by Companies, H2 2019 (Contd..9), H2 2019
Products under Development by Companies, H2 2019 (Contd..10), H2 2019
Products under Development by Companies, H2 2019 (Contd..11), H2 2019
Products under Development by Companies, H2 2019 (Contd..12), H2 2019
Products under Development by Universities/Institutes, H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..5), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..6), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..7), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..5), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..6), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Myelodysplastic Syndrome - Pipeline by 4SC AG, H2 2019
Myelodysplastic Syndrome - Pipeline by AbbVie Inc, H2 2019
Myelodysplastic Syndrome - Pipeline by Acceleron Pharma Inc, H2 2019
Myelodysplastic Syndrome - Pipeline by Actinium Pharmaceuticals Inc, H2 2019
Myelodysplastic Syndrome - Pipeline by Aeglea BioTherapeutics Inc, H2 2019
Myelodysplastic Syndrome - Pipeline by Agios Pharmaceuticals Inc, H2 2019
Myelodysplastic Syndrome - Pipeline by AIMM Therapeutics BV, H2 2019
Myelodysplastic Syndrome - Pipeline by Altor Bioscience LLC, H2 2019
Myelodysplastic Syndrome - Pipeline by Amphivena Therapeutics Inc, H2 2019
Myelodysplastic Syndrome - Pipeline by Angiocrine Bioscience Inc, H2 2019
Myelodysplastic Syndrome - Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, H2 2019
Myelodysplastic Syndrome - Pipeline by Apogenix AG, H2 2019
Myelodysplastic Syndrome - Pipeline by Aprea Therapeutics AB, H2 2019
Myelodysplastic Syndrome - Pipeline by AptaBio Therapeutics Inc, H2 2019
Number of Products under Development for Myelodysplastic Syndrome, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Products under Development by Companies, H2 2019 (Contd..9), H2 2019
Products under Development by Companies, H2 2019 (Contd..10), H2 2019
Products under Development by Companies, H2 2019 (Contd..11), H2 2019
Products under Development by Companies, H2 2019 (Contd..12), H2 2019
Products under Development by Universities/Institutes, H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..5), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..6), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..7), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..5), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..6), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Myelodysplastic Syndrome - Pipeline by 4SC AG, H2 2019
Myelodysplastic Syndrome - Pipeline by AbbVie Inc, H2 2019
Myelodysplastic Syndrome - Pipeline by Acceleron Pharma Inc, H2 2019
Myelodysplastic Syndrome - Pipeline by Actinium Pharmaceuticals Inc, H2 2019
Myelodysplastic Syndrome - Pipeline by Aeglea BioTherapeutics Inc, H2 2019
Myelodysplastic Syndrome - Pipeline by Agios Pharmaceuticals Inc, H2 2019
Myelodysplastic Syndrome - Pipeline by AIMM Therapeutics BV, H2 2019
Myelodysplastic Syndrome - Pipeline by Altor Bioscience LLC, H2 2019
Myelodysplastic Syndrome - Pipeline by Amphivena Therapeutics Inc, H2 2019
Myelodysplastic Syndrome - Pipeline by Angiocrine Bioscience Inc, H2 2019
Myelodysplastic Syndrome - Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, H2 2019
Myelodysplastic Syndrome - Pipeline by Apogenix AG, H2 2019
Myelodysplastic Syndrome - Pipeline by Aprea Therapeutics AB, H2 2019
Myelodysplastic Syndrome - Pipeline by AptaBio Therapeutics Inc, H2 2019
LIST OF FIGURES
Number of Products under Development for Myelodysplastic Syndrome, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
COMPANIES MENTIONED
4SC AG
AbbVie Inc
Acceleron Pharma Inc
Actinium Pharmaceuticals Inc
Aeglea BioTherapeutics Inc
Agios Pharmaceuticals Inc
AIMM Therapeutics BV
Altor Bioscience LLC
Amphivena Therapeutics Inc
Angiocrine Bioscience Inc
Anhui Anke Biotechnology (Group) Co Ltd
Apogenix AG
Aprea Therapeutics AB
AptaBio Therapeutics Inc
Aptevo Therapeutics Inc
Aptose Biosciences Inc
Argenx SE
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
Aurigene Discovery Technologies Ltd
Bayer AG
Bellicum Pharmaceuticals Inc
BerGenBio ASA
Bio-Path Holdings Inc
BioLineRx Ltd
BioMed Valley Discoveries Inc
Bionetix Inc
BioTheryX Inc
Boehringer Ingelheim International GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Co
Calithera Biosciences Inc
Celgene Corp
CellCentric Ltd
Cellenkos Inc
Cellerant Therapeutics Inc
Celularity Inc
Celyad SA
CheckPoint Immunology Inc
ChemioCare USA Inc
Chimerix Inc
China NT Pharma Group Co Ltd
Chordia Therapeutics Inc
Constellation Pharmaceuticals Inc
CrystalGenomics Inc
Cyclacel Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
DC Prime BV
Deciphera Pharmaceuticals Inc
Denovo Biopharma LLC
DiNonA Inc
Eli Lilly and Co
Elixirgen Therapeutics LLC
ExCellThera Inc
Fate Therapeutics Inc
Forma Therapeutics Inc
Fortress Biotech Inc
Forty Seven Inc
Fujifilm Holdings Corp
Gadeta BV
Gamida Cell Ltd
Geron Corp
GlaxoSmithKline Plc
GlycoMimetics Inc
GT Biopharma Inc
H3 Biomedicine Inc
Helocyte Biosciences Inc
HemoGenyx LLC
iCell Gene Therapeutics LLC
IGF Oncology LLC
Imago BioSciences Inc
Immune System Key Ltd
ImmunoGen Inc
Incysus Therapeutics Inc
Incyte Corp
Inmune Bio Inc
Io Therapeutics Inc
Iterion Therapeutics
Jazz Pharmaceuticals Plc
Johnson & Johnson
Jubilant Biosys Ltd
Juno Therapeutics Inc
Kainos Medicine Inc
Karyopharm Therapeutics Inc
Kiadis Pharma NV
Les Laboratoires Servier SAS
Lixte Biotechnology Holdings Inc
MacroGenics Inc
Magenta Therapeutics Inc
Mana Therapeutics Inc
Marker Therapeutics Inc
Mateon Therapeutics Inc
MediGene AG
Medivir AB
MedPacto Inc
MEI Pharma Inc
Merck & Co Inc
Merus NV
Millennium Pharmaceuticals Inc
Molecular Templates Inc
Mustang Bio Inc
Nanjing Legend Biotech Co Ltd
NantKwest Inc
Nemucore Medical Innovations Inc
Newave Pharmaceutical Inc
NexImmune Inc
Nkarta Inc
Nohla Therapeutics Inc
Novartis AG
Oncoceutics Inc
Oncoheroes Biosciences Inc
Onconova Therapeutics Inc
Oncotelic Inc
OncoTherapy Science Inc
Ono Pharmaceutical Co Ltd
Onxeo SA
Opsona Therapeutics Ltd
Orca Biosystems Inc
Orsenix Holdings BV
Oxstem Ltd
PersImmune Inc
Pfizer Inc
Pharma Mar SA
Plexxikon Inc
Prelude Therapeutics Inc
PRISM Pharma Co Ltd
Protagonist Therapeutics Inc
Rafael Pharmaceuticals Inc
Selvita SA
Sensei Biotherapeutics Inc
Senz Oncology Pty Ltd
Shanghai Yingli Pharmaceutical Co Ltd
Silence Therapeutics Plc
Sino Biopharmaceutical Ltd
SpecificiT Pharma Inc
Stelexis Therapeutics LLC
Stemline Therapeutics Inc
Sumitomo Dainippon Pharma Co Ltd
Surface Oncology Inc
Syntrix Biosystems Inc
Takara Bio Inc
Teva Pharmaceutical Industries Ltd
TheraPharm Deutschland GmbH
Toko Pharmaceutical Industries Co Ltd
Tolero Pharmaceuticals Inc
TOT Biopharm Co Ltd
Trethera Corp
Number of Products under Development for Myelodysplastic Syndrome, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
COMPANIES MENTIONED
4SC AG
AbbVie Inc
Acceleron Pharma Inc
Actinium Pharmaceuticals Inc
Aeglea BioTherapeutics Inc
Agios Pharmaceuticals Inc
AIMM Therapeutics BV
Altor Bioscience LLC
Amphivena Therapeutics Inc
Angiocrine Bioscience Inc
Anhui Anke Biotechnology (Group) Co Ltd
Apogenix AG
Aprea Therapeutics AB
AptaBio Therapeutics Inc
Aptevo Therapeutics Inc
Aptose Biosciences Inc
Argenx SE
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
Aurigene Discovery Technologies Ltd
Bayer AG
Bellicum Pharmaceuticals Inc
BerGenBio ASA
Bio-Path Holdings Inc
BioLineRx Ltd
BioMed Valley Discoveries Inc
Bionetix Inc
BioTheryX Inc
Boehringer Ingelheim International GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Co
Calithera Biosciences Inc
Celgene Corp
CellCentric Ltd
Cellenkos Inc
Cellerant Therapeutics Inc
Celularity Inc
Celyad SA
CheckPoint Immunology Inc
ChemioCare USA Inc
Chimerix Inc
China NT Pharma Group Co Ltd
Chordia Therapeutics Inc
Constellation Pharmaceuticals Inc
CrystalGenomics Inc
Cyclacel Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
DC Prime BV
Deciphera Pharmaceuticals Inc
Denovo Biopharma LLC
DiNonA Inc
Eli Lilly and Co
Elixirgen Therapeutics LLC
ExCellThera Inc
Fate Therapeutics Inc
Forma Therapeutics Inc
Fortress Biotech Inc
Forty Seven Inc
Fujifilm Holdings Corp
Gadeta BV
Gamida Cell Ltd
Geron Corp
GlaxoSmithKline Plc
GlycoMimetics Inc
GT Biopharma Inc
H3 Biomedicine Inc
Helocyte Biosciences Inc
HemoGenyx LLC
iCell Gene Therapeutics LLC
IGF Oncology LLC
Imago BioSciences Inc
Immune System Key Ltd
ImmunoGen Inc
Incysus Therapeutics Inc
Incyte Corp
Inmune Bio Inc
Io Therapeutics Inc
Iterion Therapeutics
Jazz Pharmaceuticals Plc
Johnson & Johnson
Jubilant Biosys Ltd
Juno Therapeutics Inc
Kainos Medicine Inc
Karyopharm Therapeutics Inc
Kiadis Pharma NV
Les Laboratoires Servier SAS
Lixte Biotechnology Holdings Inc
MacroGenics Inc
Magenta Therapeutics Inc
Mana Therapeutics Inc
Marker Therapeutics Inc
Mateon Therapeutics Inc
MediGene AG
Medivir AB
MedPacto Inc
MEI Pharma Inc
Merck & Co Inc
Merus NV
Millennium Pharmaceuticals Inc
Molecular Templates Inc
Mustang Bio Inc
Nanjing Legend Biotech Co Ltd
NantKwest Inc
Nemucore Medical Innovations Inc
Newave Pharmaceutical Inc
NexImmune Inc
Nkarta Inc
Nohla Therapeutics Inc
Novartis AG
Oncoceutics Inc
Oncoheroes Biosciences Inc
Onconova Therapeutics Inc
Oncotelic Inc
OncoTherapy Science Inc
Ono Pharmaceutical Co Ltd
Onxeo SA
Opsona Therapeutics Ltd
Orca Biosystems Inc
Orsenix Holdings BV
Oxstem Ltd
PersImmune Inc
Pfizer Inc
Pharma Mar SA
Plexxikon Inc
Prelude Therapeutics Inc
PRISM Pharma Co Ltd
Protagonist Therapeutics Inc
Rafael Pharmaceuticals Inc
Selvita SA
Sensei Biotherapeutics Inc
Senz Oncology Pty Ltd
Shanghai Yingli Pharmaceutical Co Ltd
Silence Therapeutics Plc
Sino Biopharmaceutical Ltd
SpecificiT Pharma Inc
Stelexis Therapeutics LLC
Stemline Therapeutics Inc
Sumitomo Dainippon Pharma Co Ltd
Surface Oncology Inc
Syntrix Biosystems Inc
Takara Bio Inc
Teva Pharmaceutical Industries Ltd
TheraPharm Deutschland GmbH
Toko Pharmaceutical Industries Co Ltd
Tolero Pharmaceuticals Inc
TOT Biopharm Co Ltd
Trethera Corp
